Insights - Of course you did – everyone did. Small-cap drug developer Intercept Pharmaceuticals (ICPT) climbed 540% in two days. Not only that, but the stock gapped up by 200 points on day one, almost … Continue Reading
Read nowLong Ideas - Tekmira Pharmaceuticals (TKMR) announced a secondary offering on Wednesday and priced the deal before Thursday’s open. Tekmira is selling 3,750,000 common stock at a price … Continue Reading
Read nowMost Popular - At PropThink, the story of the day on Friday was the sell-off in Endocyte, Inc (ECYT). Endocyte‘s lead asset is vintafolide, a folate receptor-targeting small … Continue Reading
Read nowMost Popular - Our open conference call with Tekmira Pharmaceuticals’ (TKMR) CEO Dr. Mark Murray on Thursday afternoon was a success on a number of fronts – participation, … Continue Reading
Read nowMost Popular - For those that missed our press release on Friday, PropThink will be hosting a live interview and Q&A with Dr. Mark Murray, CEO of Tekmira Pharmaceuticals (TKMR) (TKM.TO) on Thursday, October 3 … Continue Reading
Read nowLong Ideas - It’s been just under five weeks since the PropThink team laid out the investment thesis for Diadexus (DDXS). We said, “We calculate a probability weighted … Continue Reading
Read nowLong Ideas - The story of the week at PropThink was BioCryst Pharmaceuticals (BCRX), a short that rapidly went in the wrong direction as a series of unpredictable … Continue Reading
Read now